Animal-Free APRIL/TNFSF13 蛋白, Human (His)

APRIL protein (CD256) is a ligand in the tumor necrosis factor (TNF) family that can induce proliferation, regulate tumor cell growth, and may participate in mononuclear/macrophage-mediated immune process^[1]. APRIL protein is produced by myeloid cells and their precursors to accelerate cell maturation and peripheral rupture^[2]. APRIL protein has been widely used in the study of lymphatic malignancies. Human APRIL protein is a type II membrane protein with cytoplasmic domain, hydrophobic transmembrane domain and extracellular domain. Animal-Free APRIL/TNFSF13 Protein, Human (His) is produced by E. coli (A105-L250) with C-terminal His-tag.

APRIL/TNFSF13 蛋白是一种细胞因子，属于 TNF 家族的独立分泌配体。它与 TNFRSF13B/TACI 和 TNFRSF17/BCMA 结合。APRIL/TNFSF13 蛋白在肿瘤细胞生长调节中发挥作用，可能参与单核细胞/巨噬细胞介导的免疫过程^[1]。
APRIL 由骨髓细胞及其前体细胞产生，骨髓。APRIL 被周围组织保留，并且不会通过 HSPG（硫酸乙酰肝素蛋白聚糖）保留。它在骨髓中大量积累，导致细胞更快成熟和外周爆发。从感染反应来看，感染组织中的扁桃体粘膜中性粒细胞是APRIL的主要来源，而无感染症状的组织中的角化细胞是APRIL的主要来源^[2]。
APRIL 通过结合 BCMA（B 细胞成熟抗原）和 TACI（跨膜激活剂和 CAML 相互作用物）发挥作用，并与 TALL-I（也称为 BLyS 或 BAFF）竞争受体结合。可溶性 BCMA 和 TACI 特异性阻止 APRIL 结合并阻断 APRIL 刺激的原代 B 细胞增殖，可溶性 BCMA 是一种能够抑制体内抗体产生的显性失活分子。因此，除了淋巴瘤细胞系外，APRIL 还能在体外刺激原代淋巴细胞的增殖，并促进体内 B 细胞在脾脏中的积累。因此，APRIL-TALL-I和BCMA-TACI形成两个配体-两个受体途径，参与刺激B和T细胞功能。此外，APRIL 也是肿瘤细胞生长的刺激剂，尽管 TNRF 死亡配体-1 (TRDL-1) 可诱导肿瘤细胞凋亡^[1]。
它是一种 II 型膜蛋白具有胞质结构域、疏水性跨膜区和胞外结构域^[2]。小鼠和人类 APRIL 蛋白的胞外结构域 COOH 末端部分有 82% 相同，其中包含假定的受体结合结构域。人和小鼠的蛋白质序列不同，相似度高达80.91%。APRIL 蛋白最常在淋巴恶性肿瘤的背景下进行研究^[1]。

APRIL (human; 1 ng/mL; 48 h; 37 ℃) prominently restores colorectal cancer (CRC) cell migration and invasion while APRIL knockdown suppresses migration and invasion^[3].
APRIL (human; 25 or 1 ng/mL; 72 h; 37 ℃) results in an increase in proliferation rate of normal adult astrocytes and in four of eight cell lines tested^[4].

APRIL-transfected NIH-3T3 cells (1⁵ cells; s.c.; single dose) show an increased rate of tumor growth in nude mice compared with the parental cell line, and induces tumors after only 3-4 weeks^[5].

Measured by its ability to induce cell death in Jurkat cells. The ED₅₀ for this effect is 2.6-4.0 μg/mL

Human

E. coli

C-His

O75888 (A105-L250)

8741  [NCBI]

MAVLTQKQKKQHSVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQVVSREGQGRQETLFRCIRSMPSHPDRAYNSCYSAGVFHLHQGDILSVIIPRARAKLNLSPHGTFLGFVKL

Approximately 17.29 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a solution containing 0.1% sarkosyl in 1X PBS, pH8.0, trehalose.

<0.1 EU per 1 μg of the protein by the LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Yu G, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000 Sep;1(3):252-6.  [Content Brief]

  [2]. Nowacka KH, et al. Role of the APRIL molecule in solid tumors. Cytokine Growth Factor Rev. 2021 Oct;61:38-44.  [Content Brief]

  [3]. Ding W, et al. APRIL knockdown suppresses migration and invasion of human colon carcinoma cells. Clin Biochem. 2009 Nov;42(16-17):1694-8.  [Content Brief]

  [4]. Deshayes F, et al. Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene. 2004 Apr 15;23(17):3005-12.  [Content Brief]

  [5]. Hahne M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998 Sep 21;188(6):1185-90.  [Content Brief]